This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Tay-Sachs | |
|---|---|
| Name | Tay-Sachs |
| Symptoms | Progressive neurodegeneration, hypotonia, seizures |
| Complications | Respiratory failure, blindness, intellectual disability |
| Onset | Infancy, juvenile, adult forms |
| Causes | Mutations in HEXA gene |
| Risks | Ashkenazi Jewish ancestry, French-Canadian, Cajun, certain Irish communities |
| Diagnosis | Enzyme assay, genetic testing, MRI |
| Treatment | Supportive care, investigational gene therapy |
| Frequency | Rare |
Tay-Sachs is a rare, inherited neurodegenerative disorder caused by deficient activity of the hexosaminidase A enzyme. It presents classically in infancy with progressive motor and cognitive decline and is associated with characteristic findings on biochemical testing and neuroimaging. The condition has been the focus of genetic screening programs and experimental therapies, attracting attention from medical centers, research institutes, and patient advocacy organizations.
Infantile-onset disease typically appears between 3 and 6 months with loss of previously acquired skills, hypotonia, exaggerated startle response, and developmental regression; affected infants often develop seizures, blindness, and progressive motor deterioration leading to death in early childhood. Juvenile and adult presentations can feature ataxia, psychiatric manifestations, and slowly progressive neurological decline with variable cognitive impairment. Common clinical features are detected by pediatric neurologists at centers such as Johns Hopkins Hospital, Mayo Clinic, Great Ormond Street Hospital, Massachusetts General Hospital, and seen in case reports from institutions like Boston Children's Hospital, Children's Hospital of Philadelphia, University College Hospital, Sheba Medical Center, and Mount Sinai Hospital.
Tay-Sachs results from pathogenic variants in the HEXA gene on chromosome 15, leading to deficiency of hexosaminidase A and accumulation of GM2 ganglioside in neuronal lysosomes. The molecular mechanism involves impaired degradation within lysosomes, similar to other lysosomal storage disorders studied at research centers such as National Institutes of Health, European Molecular Biology Laboratory, Broad Institute, Salk Institute, and Cold Spring Harbor Laboratory. Populations with higher carrier frequencies include groups documented in genetic studies at Hebrew University of Jerusalem, McGill University, Université Laval, and community health programs in New York City, Montreal, Boston, and New Orleans. Foundational biochemical work was described by investigators associated with institutions like Rockefeller University and Yale University.
Diagnostic evaluation includes measurement of hexosaminidase A activity in serum or leukocytes and identification of pathogenic HEXA variants by molecular genetic testing at diagnostic laboratories such as those affiliated with Mayo Clinic Laboratories, Quest Diagnostics, ARUP Laboratories, Genetic Testing Laboratories (GTL), and university hospitals. Neuroimaging with magnetic resonance imaging interpreted by neuroradiologists at centers like Cleveland Clinic, Stanford Health Care, and UCLA Health may show cerebral and cerebellar atrophy and signal changes; ophthalmologic exam by specialists at Wills Eye Hospital or Bascom Palmer Eye Institute can reveal a cherry-red spot of the macula. Newborn screening programs coordinated by state public health departments and analyzed in collaborations with agencies such as Centers for Disease Control and Prevention, Health Resources and Services Administration, and regional labs contribute to early detection.
There is no definitive cure; management focuses on multidisciplinary supportive care provided by teams at pediatric neurology and metabolic centers including Children's National Hospital, Royal Children's Hospital (Melbourne), The Hospital for Sick Children (Toronto), and rehabilitation services at institutions such as Spaulding Rehabilitation Hospital. Symptomatic treatments address seizures, feeding difficulties, respiratory care, and spasticity using protocols developed at Johns Hopkins Hospital and Massachusetts General Hospital. Experimental approaches under investigation by research consortia at University of Pennsylvania, University of California, San Francisco, University of Oxford, Karolinska Institutet, and biotech firms include gene therapy, enzyme replacement strategies, and substrate reduction therapy; clinical trials have been sponsored or overseen by organizations like National Institutes of Health, European Medicines Agency, and private foundations.
Infantile Tay-Sachs typically leads to death by early childhood, whereas juvenile and adult forms have more variable courses with slower progression and prolonged survival into adolescence or adulthood. Epidemiological data on carrier frequencies and incidence have been reported in populations studied by researchers at Hebrew University of Jerusalem, McGill University, Université Laval, Centers for Disease Control and Prevention, Public Health England, and academic departments at Columbia University and University of California, San Diego. Historical reductions in disease incidence in some communities have been attributed to carrier screening initiatives modeled by programs at Brigham and Women's Hospital and community health organizations in Brooklyn and Montreal.
Prevention strategies emphasize carrier screening, cascade testing, and genetic counseling offered by clinical genetics teams at centers including Mount Sinai Hospital, Cleveland Clinic, UCSF Medical Center, Royal Free Hospital, and public health services in regions such as Ontario and Quebec. Community-based screening programs involving organizations like Jewish Genetic Screening groups, university clinics, and public health departments have reduced disease incidence through premarital and prenatal counseling, preimplantation genetic diagnosis performed by IVF centers at Cornell University and Weill Cornell Medicine, and newborn screening initiatives coordinated with agencies such as Centers for Disease Control and Prevention and Health Resources and Services Administration.